GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their GS010 treatment for LHON provides sustained visual acuity 78 weeks after a dose escalating… Read More »GenSight Biologics Inc. reports sustained visual acuity 78 weeks after gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
Stealth BioTherapeutics Inc., a biotechnology company based in Newtown, Massachusetts, have announced the initiation of a Phase I study in AMD to test the safety… Read More »Stealth BioTherapeutics intiates Phase I study with a novel compound targeting mitochondrial dysfunction in retinal disorders.
Horama SAS, a gene therapy company based in Paris and specialising in the development of treatments of ophthalmic disease, has announced the receipt of €4… Read More »Paris-based gene therapy company Horama SAS raises €4M in venture capital funding for the development of retinal disease therapies.
GenSight Biologics S.A. (Euronext: SIGHT) has announced the receipt of Orphan Drug Designation in Europe for its experimental retinitis pigmentosa (RP) treatment, “GS030”. According to… Read More »French biotechnology company GenSight receives orphan designation for retinitis pigmentosa gene therapy treatment in Europe.
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced a new initiative to provide free genetic testing for eligible patients to… Read More »Spark Therapeutics Inc., (NASDAQ:ONCE) announces free genetic testing and counselling services for patients with inherited retinal degenerations.
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), located in Cambridge Massachusetts, has announced the execution of an exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche… Read More »Eleven Biotherapeutics announces deal with Roche for the licensing of IL-6 antibody technology, including treatments for diabetic macular edema and uveitis.
Allergan plc. (NYSE:AGN), based in Dublin, Ireland, has announced the acquisition of Michigan-based gene therapy company RetroSense Therapeutics in an upfront all-cash based transaction for… Read More »Allergan acquires gene therapy company RetroSense Therapeutics LLC for $60M upfront cash.
A US public company based in San Diego, Pfenex Inc. (NYSE MKT: PFNX) has announced that is has regained commercial rights to a biosimilar of… Read More »US company Pfenex Inc. announces a regain of full rights from Pfizer Inc. to Lucentis biosimilar candidate (PF582) under-going clinical evaluation.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), previously Avalanche Biotechnologies Inc., and Editas Medicine, Inc. (NASDAQ:EDIT) have announced a collaboration to employ gene editing technology (CRISPR) in the… Read More »Advernum and Editas join forces to explore applications of gene editing to ocular disease.
GenSight Biologics S.A. (Euronext: SIGHT) has raised over €40M on the Euronext exchange following a venture capital fundraising of €36M approximately 12 months prior. The… Read More »GenSight SA (Paris, France) raises €40M in IPO on Euronext.